文献速递神经肿瘤

精准放疗:IDH突变胶质瘤管理演进中的生物标志物引导放疗策略

Fine-tuning the beam: Biomarker-guided radiation strategies in the evolving management of isocitrate dehydrogenase (IDH)-mutant glioma.
PubMed 文献 · Neuro Oncol · 2026-10-10

IDH突变胶质瘤的标准治疗包括序贯放化疗,III期INDIGO试验使vorasidenib获批用于活检或切除后WHO 2级IDH1/2突变星形细胞瘤或少突胶质细胞瘤。IDH抑制剂与放疗的时序关系、能否用于高级别或高危人群尚不明确,本文探讨生物标志物引导的放疗策略以优化患者选择、疗效监测和治疗时机。

要点

  • vorasidenib已获批用于活检或切除后WHO 2级IDH1/2突变星形细胞瘤或少突胶质细胞瘤。
  • IDH抑制剂与放疗的先后、联合或替代关系尚未确定,需生物标志物指导。
  • IDH抑制剂能否外推至高级别或高危患者仍未知,需进一步研究。

核心结论

  • IDH抑制剂是IDH突变胶质瘤的重要进展,但其与放疗的最佳整合方式及适用人群尚存争议,需开发基于生物标志物的实用策略。

研究设计与样本

  • 本文为综述,基于III期INDIGO试验结果及IDH突变胶质瘤相关研究,讨论生物标志物引导的放疗策略。

主要发现

  • III期INDIGO试验结果促使vorasidenib获批用于活检或切除后WHO 2级IDH1/2突变星形细胞瘤或少突胶质细胞瘤。
  • IDH抑制剂应于放疗前、联合或替代放疗尚存争议,能否用于高级别或高危患者未知。

临床怎么用

  • 可基于生物标志物选择适合IDH抑制剂的患者,并监测治疗反应以确定最佳治疗策略和时序。

局限性

  • IDH抑制剂与放疗的最佳时序和联合方式尚未确定,高级别或高危患者的获益未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sequential chemoradiotherapy remains a standard treatment option for patients with isocitrate dehydrogenase (IDH)-mutant gliomas. The results of the phase III INDIGO trial have led to the recent regulatory approval of vorasidenib, a brain-penetrant IDH1 and IDH2 inhibitor, indicated for patients with IDH1- or IDH2-mutant WHO grade 2 astrocytoma or oligodendroglioma after biopsy or resection. While IDH inhibitors represent a significant advancement for patients with IDH-mutant glioma, there is substantial controversy regarding which patients are most likely to derive benefit from IDH inhibition and how this strategy can be optimally integrated into clinical practice. Specifically, whether IDH inhibitors should be used prior to, in conjunction with or potentially in lieu of radiation-based treatment strategies are fundamental questions for the neuro-oncology community. Additionally, whether IDH inhibitors can be extrapolated to higher-grade disease settings or utilized in higher-risk patient populations remains unknown. These open questions provide an opportunity for the field of radiation oncology to develop pragmatic biomarker-based approaches to guide patient selection, to monitor treatment response and to identify optimal treatment strategy and timing/sequencing of treatment. Several candidate biomarkers have emerged for IDH-mutant glioma with unique potential to be rationally integrated into radiation oncology workflows to personalize care.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Marciscano AE, Shih HA, Niyazi M, et al. Fine-tuning the beam: Biomarker-guided radiation strategies in the evolving management of isocitrate dehydrogenase (IDH)-mutant glioma. Neuro Oncol. 2026. PMID: 42860048. doi:10.1093/neuonc/noag169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。